Werewolf Therapeutics, Inc. HOWL
1.01 USD -0.01 (-0.98%)
At closeNov 6, 2026, 4:00 PM EST
1.01 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
0.9826 Day range 1.03
0.308 52-week range 1.20
- YTD
- +59.31%
- 1 year
- -15.83%
Financial health
Altman Z-Score
-26.27 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C+2 / 5 overall
- DCF 4
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 4
Valuation
P/E -0.5×
FY 2019 5y median -1.1× FY 2025
P/S 0.0×
FY 2019 5y median 3.6× FY 2025
P/B 1.2×
FY 2019 5y median 1.2× FY 2025
P/FCF -0.5×
FY 2019 5y median -1.3× FY 2025
EV/EBITDA 0.4×
FY 2019 5y median 0.2× FY 2025
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2025
FCF Yield -206.8%
FY 2019 5y median -74.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 3.8% FY 2025
Operating Margin 0.0%
FY 2019 5y median -203.1% FY 2025
Net Margin 0.0%
FY 2019 5y median -187.4% FY 2025
ROE -245.2%
FY 2019 5y median -44.0% FY 2025
ROIC -173.4%
FY 2019 5y median -40.5% FY 2025
ROA -87.6%
FY 2019 5y median -33.6% FY 2025
Growth (YoY)
Revenue -100.0%
FY 2019 FY 2025
Operating Income 17.6%
FY 2019 FY 2025
EPS (diluted) 18.4%
FY 2019 FY 2025
Free Cash Flow -6.8%
FY 2019 FY 2025
Financial Health
Current Ratio 1.6×
FY 2019 5y median 7.1× FY 2025
Quick Ratio 1.6×
FY 2019 5y median 7.1× FY 2025
Debt / Equity 0.4×
FY 2019 5y median 0.4× FY 2025
Net Debt / EBITDA 0.9×
FY 2019 5y median 2.2× FY 2025
Interest Coverage -11.5×
FY 2019 5y median -11.5× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31